PixarBio (PixarBio) Short-Term Capital Lease Obligation : $0.00 Mil (As of Sep. 2016)

View and export this data going back to 2016. Start your Free Trial

What is PixarBio Short-Term Capital Lease Obligation?

PixarBio's Short-Term Capital Lease Obligation for the quarter that ended in Sep. 2016 was $0.00 Mil.

PixarBio Short-Term Capital Lease Obligation Historical Data

The historical data trend for PixarBio's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PixarBio Short-Term Capital Lease Obligation Chart

PixarBio Annual Data

Trend

Dec14

Dec15

Short-Term Capital Lease Obligation

PixarBio Quarterly Data
	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial					-	-	-	-	-

PixarBio Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

PixarBio Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of PixarBio's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

PixarBio (PixarBio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PixarBio Corp (GREY:PXRB) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Boston Avenue, Suite 1875, Medford, MA, USA, 02155

Website

https://www.pixarbio.com

PixarBio Corp is a specialty pharmaceutical company focused on preclinical and clinical commercial development of therapeutic drug delivery systems for post-operative pain. The company's lead clinical candidate, NeuroRelease is a non-opioid / non-opiate preclinical stage product intended for the treatment of surgical pain, with planned future indications for chronic pain. NeuroRelease blocks nociceptive and neuropathic pain signals arising from temperature and pressure stimuli without affecting motor function, which is intended to allow for effective treatment without delaying post-surgical physical therapy.